HR 3277, the Ensuring Lasting Smiles Act, requires group health plans and health insurance issuers to cover medically necessary outpatient and inpatient treatments for congenital anomalies or birth defects primarily affecting the eyes, ears, teeth, mouth, or jaw. This includes reconstructive procedures, dental/orthodontic support during treatment, and follow-up care, but excludes purely cosmetic surgery not tied to a medical diagnosis. Cost-sharing (like copays) for these services must not be stricter than for other medical benefits. The law takes effect for plan years beginning January 1, 2026, and mandates insurers to provide notice about this coverage to beneficiaries.
The ETHIC Act (HR 3269) limits how many patents pharmaceutical companies can assert in lawsuits against generic drug and biosimilar manufacturers. Specifically, it prohibits a company from claiming more than one patent per "Patent Group" (commonly owned patents linked through disclaimers) in an infringement case involving a generic drug applicant or biosimilar product. This directly affects generic drug makers (under FDA's 505(b)(2) or 505(j) pathways) and biosimilar developers (under the Public Health Service Act), reducing the ability of brand-name companies to use stacked patents to delay competition. The law applies to applications submitted after its enactment date.
This bill amends the Higher Education Act to clarify eligibility for Public Service Loan Forgiveness (PSLF). It corrects a technical wording error in the law that previously required borrowers to be *currently employed* in public service at the time of application. The change specifies that borrowers only need to have *completed* 10 years (120 payments) of qualifying public service employment to qualify. This directly affects federal student loan borrowers working in government or nonprofit roles who were previously disqualified due to the outdated wording. The amendment removes a barrier preventing eligible borrowers from receiving loan forgiveness they earned.
The Certainty for Our Energy Future Act ends tax credits for new wind and solar energy projects that begin construction after December 31, 2030, effective January 1, 2026. It also denies clean energy tax benefits to companies controlled by governments of China, Russia, Iran, or North Korea. The bill uses existing IRS guidelines to define when construction begins for projects, avoiding new bureaucratic rules. Treasury must issue implementation guidance within 180 days, with country-related restrictions taking effect 180 days after that guidance is published.
HR 3304, the Providing Child Care for Police Officers Act of 2025, establishes a federal grant program to help law enforcement agencies provide child care for officers' minor children during nonstandard shifts. The program awards competitive 3-year grants to state or local "lead agencies" (like state child care offices) to fund child care services through eligible law enforcement agencies or consortia, with 20% of funds reserved for small agencies (under 200 officers). Grants cover startup costs, provider training, sick child care, facility construction, and other needs, requiring local matching funds (10% to 33% over three years). The program is authorized for $24 million annually from 2026-2030 and includes studies to evaluate its impact on child care access for officers and other first responders.
This bill prohibits corporal punishment in schools receiving federal funding, defining it as any physical force causing pain for discipline. It requires schools to notify parents within 24 hours of any corporal punishment incident and mandates states to submit school climate reports detailing efforts to reduce exclusionary discipline practices like suspensions and expulsions. The bill establishes a grant program to help schools implement positive behavioral interventions, such as restorative justice and trauma-informed care, while requiring staff training on these approaches. The bill applies to public schools and other schools receiving federal funds but does not affect private schools or home schools that don't receive federal funding.
HR 2623, the Innovative Therapies Centers of Excellence Act of 2025, directs the Department of Veterans Affairs to establish at least five specialized medical centers focused on treating veterans with specific conditions like PTSD, depression, chronic pain, and substance use disorders using innovative therapies. These centers must meet strict criteria, including academic partnerships with medical schools, research capabilities, veteran advisory committees, and data-sharing systems for evaluating treatment effectiveness. The bill authorizes $30 million annually for these centers' research and education activities and requires the VA to submit annual reports to Congress on their operations and findings. It directly affects veterans seeking advanced treatments for covered conditions through VA facilities and establishes a peer review process to select designated centers based on scientific merit.
HR 1030, the Flight 293 Remembrance Act, creates a program to support families of U.S. military personnel who died in non-combat plane crashes since 1984 (and earlier crashes with documented records). The bill requires the Defense and Veterans Affairs Secretaries to build a public database of crash victims' details, provide families with personalized guidance on accessing benefits and support services, and establish a dedicated contact point for ongoing assistance. It also mandates a two-year report to Congress assessing the program's progress, family satisfaction, and recommendations for improvement. The law ensures non-discrimination protections apply to all assistance provided under the program. This bill directly affects families of service members lost in non-combat aviation incidents.
This bill allows businesses to immediately deduct research and development (R&D) costs instead of spreading them over 60 months, directly benefiting companies investing in innovation. It increases the refundable R&D credit cap for small businesses from $250,000 to $750,000 over time, with specific phase-in amounts starting in 2025. Additionally, it expands access for startups by raising the gross receipts threshold for eligibility from $5 million to $15 million and increasing credit rates for qualified small businesses. These changes aim to make R&D tax incentives more accessible and valuable for smaller companies and new ventures.
S 1650, the VA Employee Fairness Act of 2025, modifies collective bargaining rules for Veterans Health Administration (VHA) employees. It removes existing subsections (b), (c), and (d) from Section 7422 of Title 38 and redesignates the current subsection (e) as (b). This change directly affects VHA health care workers who negotiate with management over wages, hours, and working conditions. The bill clarifies that these modifications do not impact the Secretary's existing authority over incentive pay and expedited hiring under Section 706 of Title 38.
This bill bans the commercial provision of conversion therapy - defined as paid attempts to change a person's sexual orientation or gender identity - as it is deemed ineffective and harmful. It directly affects therapists, clinics, and any commercial entity offering such services, while exempting gender transition support and non-discriminatory counseling. Key mechanisms include prohibiting paid conversion therapy, banning deceptive advertising (e.g., claiming it’s harmless), and empowering the Federal Trade Commission and state attorneys general to enforce penalties. The law focuses on preventing fraud by stopping profit-driven practices with no scientific basis, aligning with professional consensus on the risks.
HR 3243, the Therapeutic Fraud Prevention Act of 2025, bans the provision of paid conversion therapy aimed at changing a person's sexual orientation or gender identity, and prohibits advertising such therapy as effective, safe, or without risk. It directly affects LGBTQ+ individuals and their families who might be targeted by these practices, as professionals have determined conversion therapy is ineffective and harmful. The law treats violations as deceptive acts under consumer protection laws, empowering the Federal Trade Commission and state attorneys general to enforce it through civil actions. It explicitly excludes legitimate gender transition support and non-discriminatory counseling from the ban.
